Alcoholic liver disease: a synopsis of the Charles Lieber's Memorial Symposia 2009-2012

Manuela G Neuman; Lawrence Cohen; Samir Zakhari; Radu M Nanau; Sebastian Mueller; Michelle Schneider; Charles Parry; Romina Isip; Helmut K Seitz

doi:10.1093/alcalc/agu021

Alcoholic liver disease: a synopsis of the Charles Lieber's Memorial Symposia 2009-2012

Alcohol Alcohol. 2014 Jul-Aug;49(4):373-80. doi: 10.1093/alcalc/agu021. Epub 2014 May 9.

Authors

Manuela G Neuman¹, Lawrence Cohen², Samir Zakhari³, Radu M Nanau⁴, Sebastian Mueller⁵, Michelle Schneider⁶, Charles Parry⁷, Romina Isip⁴, Helmut K Seitz⁵

Affiliations

¹ In Vitro Drug Safety and Biotechnology, University of Toronto, Toronto, ON, Canada Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada manuela.neuman@utoronto.ca.
² Division of Gastroenterology, Sunnybrook Health Sciences Centre, Department of Medicine, Medicine, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
³ Division of Metabolism and Health Effects, National Institute on Alcohol Abuse and Alcoholism, National Institutes of Health, Bethesda, MD, USA.
⁴ In Vitro Drug Safety and Biotechnology, University of Toronto, Toronto, ON, Canada Department of Pharmacology and Toxicology, Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
⁵ Centre of Alcohol Research, University of Heidelberg and Department of Medicine (Gastroenterology and Hepatology), Salem Medical Centre, Heidelberg, Germany.
⁶ Alcohol and Drug Abuse Research Unit, Medical Research Council, Stellenbosch University, Cape Town, South Africa.
⁷ Alcohol and Drug Abuse Research Unit, Medical Research Council, Stellenbosch University, Cape Town, South Africa Department of Psychiatry, Stellenbosch University, Cape Town, South Africa.

Abstract

This paper is based upon the 'Charles Lieber Satellite Symposia' organized by Manuela G. Neuman at each of the 2009-2012 Research Society on Alcoholism (RSA) Annual Meetings. The presentations represent a broad spectrum dealing with alcoholic liver disease (ALD). In addition, a literature search (2008-2013) in the discussed area was performed in order to obtain updated data. The presentations are focused on genetic polymorphisms of ethanol metabolizing enzymes and the role of cytochrome P4502E1 (CYP2E1) in ALD. In addition, alcohol-mediated hepatocarcinogenesis, immune response to alcohol and fibrogenesis in alcoholic hepatitis as well as its co-morbidities with chronic viral hepatitis infections in the presence or absence of human deficiency virus are discussed. Finally, emphasis was led on alcohol and drug interactions as well as liver transplantation for end-stage ALD.

Publication types

Congress
Research Support, Non-U.S. Gov't

MeSH terms

Antiretroviral Therapy, Highly Active / adverse effects
Cytochrome P-450 CYP2E1 Inducers / pharmacokinetics
Cytochrome P-450 CYP2E1 Inducers / pharmacology
Drug Interactions
Ethanol / pharmacokinetics*
HIV Infections / complications
HIV Infections / drug therapy
Hepatitis C, Chronic / complications
Hepatitis C, Chronic / metabolism
Histamine H2 Antagonists / adverse effects
Humans
Liver Diseases, Alcoholic / complications
Liver Diseases, Alcoholic / enzymology*
Liver Diseases, Alcoholic / genetics
Liver Transplantation / mortality

Substances

Cytochrome P-450 CYP2E1 Inducers
Histamine H2 Antagonists
Ethanol